Phase i trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2480-2486

  Tomlinson, Benjamin K ^a   Thomson, James A ^b   Bomalaski, John S ^b   Diaz, Monica ^b   Akande, Taiwo ^a   Mahaffey, Nichole ^a   Li, Tianhong ^a,c   Dutia, Mrinal P ^a,c   Kelly, Karen ^a   Gong, I Yeh ^a   Semrad, Thomas ^a   Gandara, David R ^a   Pan, Chong Xian ^a,c   Lara, Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Polaris Pharmaceuticals Inc   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CITRULLINE; DOCETAXEL; DRUG ANTIBODY; PEGARGIMINASE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; HYDROLASE; MACROGOL DERIVATIVE; TAXOID;

ADULT; ADVANCED CANCER; ALLERGIC REACTION; ALOPECIA; AMINO ACID BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBODY TITER; ARTICLE; BLOOD CLOTTING TIME; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOGENICITY; INJECTION SITE PAIN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NOSE OBSTRUCTION; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SKIN PRURITUS; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYMUS CANCER; UNSPECIFIED SIDE EFFECT; URTICARIA; WEAKNESS; ADVERSE DRUG REACTION; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; METABOLISM; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARGININE; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; HYDROLASES; MALE; NEOPLASM STAGING; NEOPLASMS; POLYETHYLENE GLYCOLS; TAXOIDS; TREATMENT OUTCOME;

EID: 84941962550     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2610     Document Type: Article

References (25)

1. Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia-still to be defined? Br J Haematol 2004; 125:117-27.
2. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancers sensitive to arginine deprivation. Cancer 2004;100:826-33.
3. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14: 1049-57.
4. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009; 69:700-8.
5. Miyazaki K, Takaku H, Umeda M, Fujita T, Huang WD, Kimura T, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 1990;50:4522-7.
6. Holtsberg FW, Ensor CM, Steiner MR, Bomalaski JS, Clark MA. Poly (ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 2002;80: 259-71.
7. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20, 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62: 5443-50.
8. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 2012;106: 1481-5.
9. Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 2003;50:1214-6.
10. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28:2220-6.
11. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004;22:1815-22.
12. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103: 954-60.
13. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23: 7660-8.
14. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 2013; 31:425-34.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
16. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-20.
17. Group P. Phase 3 ADI-PEG 20 versus placebo in subjects with advanced hepatocellular carcinoma who have failed prior systemic therapy[Internet]; 2014 [cited 2014 May 7]. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT01287585
18. Szlosarek PW, Steele J, Sheaff M, Szyszko T, Ellis S, Nolan L, et al. A randomised phase II trial of pegylated arginine deiminase in patients with malignant pleural mesothelioma [oral abstract]. In: Proceedings of the 15th World Conference on Lung Cancer; 2013 October 27-31; Sydney, Australia. Abstract nr MO09.02
19. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
20. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000;18:2095-103.
21. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
22. Berthold DR, Pond GR, Soban F, deWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5.
23. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
24. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-7.
25. Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071-6.